market access
The pharma company with a build-as-you go approach
November 30 by Leila HawkinsPharma IQ speaks to Amarin’s SVP for Europe about the company’s unique market strategy
Integrate or disintegrate?
October 30 by Alan KennedyIntroducing the dos and don't of collaborative working in a pharma-logistics contextSince its emergence as a realistic organisational model in the final quarter of the last century the business potent...
Ensuring Effective Translations – Prepare Translation
October 27 by Andrew LoveContinuing in this series of articles expanding on Ensuring Effective Translations, the next set of tips are to help you make sure that the information you are giving to your service provider is well...
Connect with Pharma & Biotech Key Players - Your Ultimate Resource Pack
October 01 by Pharmaceuticals & Biotechnology EditorIn this whitepaper you will find out what it takes to successfully engage with pharma and biotech key players. Are you looking for a ways to showcase your solution in front of pharma and biotech i...
Martyrs & Models: Early Returns from the AMNOG Era
February 06 by Pharmaceuticals & Biotechnology EditorDuring the past few months, IQWiG has made several decisions public for recently reviewed drugs. For the first time, a body of evidence exists which can shed some light upon how restrictive and...
The Impact of Direct Nucleation Control on Crystal Size Distribution in Pharmaceutical Crystallization Processes
January 25 by Pharmaceuticals & Biotechnology EditorThe control of crystal size distribution (CSD) in pharmaceutical crystallization is of primary importance, as downstream processes such as filtration or drying are greatly affected by the properties...
Orphan Drugs – Reinventing Economies of Scale
November 16 by Cristina FalcãoEconomies of scale come in many flavors. Including the oddity flavor where the number of manufactured products decreases and the size of markets shrink. Orphan drugs are economies of scale’...
Portuguese Hospitals Block Access to New Medicines as Retail Drug Sector Expected to Meet Savings Goal
September 29 by Tania Rodrigues, an analyst at IHS Global InsightAccess to expensive medicines is becoming increasingly difficult in Portuguese public hospitals, while savings with retail pharmacy expenditure are expected to be better than projections in the Memora...
EU Accession Reference Pricing
September 28 by Pharmaceuticals & Biotechnology EditorInternational reference pricing has grown from an evolving cost-containment philosophy in Western Europe, to a trusted policy tool readily adopted by emerging markets around the world. As, Cro...
Keeping the Pharma Sales Door Open
August 03 by Pharma IQDaniel Schick, Executive Director, Commercial Affairs & Key Account Management for Janssen-Cilag, spoke to Andrea Charles from Pharma IQ, about the current challenges facing pharmaceutic...
Das Arzneimittelsparpaket: Wie kann sich die Pharmaindustrie auf die neuen Rahmenbedingungen einstellen?
July 28 by Pharma IQIn this Pharma IQ podcast, Isabel Henkel, Director, Access & Reimbursement at Johnson & Johnson Medical, talks about how the pharma industry needs to adjust to the new requirements of the...
EU Price-Cut Pandemic: Managing with Discipline
July 01 by Cyrus ChowdhuryRecent weeks have revealed the immediate result of the European debt crisis: adoption of austerity measures, many of which prioritise an easy target, pharmaceutical expenditure. Governments tend...